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Oral anticoagulant agents (OAC) are used to reduce the risk of embolic complications. Paradoxically, whenever 
an embolic complication as ischemic stroke occurs, the per-
ceived risk of hemorrhagic complications limits the options 
for acute reperfusion therapy. As such, intravenous thrombo-
lytics (IVT) for acute ischemic stroke are contra-indicated for 
patients taking direct anticoagulants (DOACs) and vitamin K 
antagonists (VKAs) with international normalized ratio (INR) 
above 1.7.1 For patients with ischemic stroke caused by an 
intracranial large vessel occlusion in the anterior circulation, 
endovascular treatment (EVT) is the only effective alterna-
tive.2–5 However, it is not known whether prior use of OAC 
affects outcomes after EVT. In a single-center retrospective 
study, hemorrhage rates after EVT in patients ineligible for 
intravenous thrombolysis were similar for patients who were 
anticoagulated and patients not on anticoagulant therapy.6
The aim of the present study was to compare outcomes 
after EVT between patients with and without prior use of 
Background and Purpose—The use of oral anticoagulants (OAC) is considered a contra-indication for intravenous 
thrombolytics as acute treatment of ischemic stroke. However, little is known about the risks and benefits of endovascular 
treatment in patients on prior OAC. We aim to compare outcomes after endovascular treatment between patients with and 
without prior use of OAC.
Methods—Data of patients with acute ischemic stroke caused by an intracranial anterior circulation occlusion, included in the 
nationwide, prospective, MR CLEAN Registry between March 2014 and November 2017, were analyzed. Outcomes of 
interest included symptomatic intracranial hemorrhage and functional outcome at 90 days (modified Rankin Scale score). 
Outcomes between groups were compared with (ordinal) logistic regression analyses, adjusted for prognostic factors.
Results—Three thousand one hundred sixty-two patients were included in this study, of whom 502 (16%) used OAC. There was 
no significant difference in the occurrence of symptomatic intracranial hemorrhage between patients with and without prior 
OACs (5% versus 6%; adjusted odds ratio, 0.63 [95% CI, 0.38–1.06]). Patients on OACs had worse functional outcomes 
than patients without OACs (common odds ratio, 0.57 [95% CI, 0.47–0.66]). However, this observed difference in functional 
outcome disappeared after adjustment for prognostic factors (adjusted common odds ratio, 0.91 [95% CI, 0.74–1.13]).
Conclusions—Prior OAC use in patients treated with endovascular treatment for ischemic stroke is not associated with an 
increased risk of symptomatic intracranial hemorrhage or worse functional outcome compared with no prior OAC use. 
Therefore, prior OAC use should not be a contra-indication for endovascular treatment.   (Stroke. 2020;51:1781-1789. 
DOI: 10.1161/STROKEAHA.119.028675.)
Key Words: anticoagulants ◼ intracranial hemorrhage ◼ outcome ◼ stroke ◼ thrombectomy
Received December 14, 2019; final revision received March 7, 2020; accepted April 8, 2020.
From the Department of Neurology (R.-J.B.G., W.H.H., R.J. v.O.) and Department of Radiology (A.P., W.H.v.Z.), Cardiovascular Research Institute 
Maastricht (CARIM), Maastricht University Medical Center; Department of Neurology (R.A.v.d.G., J.M.v.R., D.W.J.D., B.R.), Department of Radiology 
& Nuclear Medicine (R.A.v.d.G., B.R.), and Department of Public Health (H.F.L.), Erasmus MC, University Medical Center, Rotterdam; School for Mental 
Health and Sciences (Mhens), Maastricht University (A.P.); Department of Neurology, Haaglanden Medical Center, The Hague (I.v.d.W.); and Department 
of Neurology, Leiden University Medical Center (I.v.d.W.).
*Drs Goldhoorn and van de Graaf contributed equally.
†A list of all MR CLEAN Registry Investigators is given in the Appendix.
Presented in part at the European Stroke Organisation Conference, Milan, Italy, May 22–24, 2019.
The Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.119.028675.
Correspondence to Robert-Jan B. Goldhoorn, MD, Department of Neurology, Maastricht University Medical Center, Room 4.R1.032, P. Debyelaan 25, 
6229 HX Maastricht, the Netherlands. Email robertjan.goldhoorn@mumc.nl
© 2020 The Authors. Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access 
article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any 
medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
Endovascular Treatment for Acute Ischemic  
Stroke in Patients on Oral Anticoagulants
Results From the MR CLEAN Registry
Robert-Jan B. Goldhoorn , MD*; Rob A. van de Graaf, MD*;  
Jan M. van Rees, BSc; Hester F. Lingsma, PhD; Diederik W.J. Dippel, MD, PhD;  
Wouter H. Hinsenveld, MD; Alida Postma, MD, PhD; Ido van den Wijngaard, MD, PhD;  
Wim H. van Zwam, MD, PhD; Robert J. van Oostenbrugge, MD, PhD; Bob Roozenbeek, MD, PhD;  
on behalf of the MR CLEAN Registry Investigators†
DOI: 10.1161/STROKEAHA.119.028675Stroke is available at https://www.ahajournals.org/journal/str
D
ow
nloaded from
 http://ahajournals.org by on June 5, 2020
1782  Stroke  June 2020
OACs in a large cohort representative of Dutch clinical 
practice.
Methods
Data Availability Statement
Source data will not be made available because of legislative issues 
on patient privacy. However, detailed analytic methods and study 
materials, including log files of statistical analyses, will be made 
available to other researchers on reasonable request to the corre-
sponding author.
Study Design and Patient Population
Patients enrolled in the MR CLEAN Registry (Multicenter 
Randomized Clinical Trial of Endovascular Treatment of Acute 
Ischemic Stroke in the Netherlands) from March 2014 until November 
2017 were included in this study. The MR CLEAN Registry is a mul-
ticenter, prospective, observational cohort with EVT treated patients 
in the Netherlands.5 All patients undergoing an EVT procedure (de-
fined as entry into the angiography suite and arterial puncture) for 
acute ischemic stroke in the anterior and posterior circulation have 
been registered in the MR CLEAN Registry. EVT consisted of arte-
rial catheterization with a microcatheter to the level of the occlusion, 
followed by mechanical thrombectomy with or without delivery of 
a thrombolytic agent. For the present study, we used the following 
inclusion criteria: arterial puncture within 6.5 hours after symptom 
onset; age ≥18; occlusion of intracranial carotid (ICA, ICA-T), 
middle (M1/M2) or anterior (A1/A2) cerebral artery, demonstrated 
by baseline CT angiography, treatment in a MR CLEAN trial center, 
and available data on prior OAC use. ASPECT score on baseline 
noncontrast CT and collateral status on CT angiography were scored 
using definitions described previously.7,8 A central medical ethics 
committee evaluated the study protocol of the MR CLEAN Registry 
and granted permission to perform the study as a registry.
Prior OAC Use
Anticoagulant use before EVT was defined as any VKA or DOAC 
use before the EVT as reported on the case report form of the MR 
CLEAN Registry (www.mrclean-trial.org). INR was reported by 
local investigators, which was taken from blood samples at baseline 
before administration of IVT (if indicated). Anti-Xa activity, diluted 
thrombin time, and activated partial thromboplastin time were not 
measured routinely.
Outcome Measures
Outcomes of interest were reperfusion grade according to postinter-
vention digital subtraction angiography, postintervention neurological 
deficit, occurrence of symptomatic intracranial hemorrhage (sICH), 
ischemic stroke progression, functional outcome, and mortality at 
90 days. Reperfusion was scored by the extended Thrombolysis in 
Cerebral Ischemia (eTICI) score,9 which ranges from grade 0 no re-
perfusion to grade 3 complete reperfusion. An independent core lab, 
blinded for clinical outcome, assessed all imaging.
Postintervention neurological deficit was measured with the 
National Institutes of Health Stroke Scale (NIHSS) score, with higher 
scores indicating greater deficit.10
An intracranial hemorrhage was considered symptomatic if the 
patient had died or had deteriorated neurologically (a decline of at 
least 4 points on the NIHSS), and the hemorrhage was related to the 
clinical deterioration (according to Heidelberg criteria11). Ischemic 
stroke progression was defined as neurological deterioration of at 
least 4 points on the NIHSS, in which an intracranial hemorrhage 
was excluded with CT as the cause of the deterioration. Functional 
outcome was measured with the modified Rankin Scale (mRS) score 
at 90 days, ranging from 0 no symptoms to 6 death.12
Missing Data
Missing NIHSS scores were retrospectively scored with a stan-
dardized score chart based on information from the reported neu-
rological examination. If successful reperfusion was not achieved 
during EVT, the time of last contrast bolus injection was used as 
a proxy for time of reperfusion. Any mRS score of 0 to 5 assessed 
within 30 days was considered missing. These values were, there-
fore, replaced by mRS scores derived from multiple imputation for 
the (multivariable) regression analysis.13 All descriptive analyses 
include patients with complete data, while all regression models in-
clude all patients with imputed data.
Statistical Analysis
Baseline characteristics were analyzed using standard statistics. We 
used ordinal logistic regression models to determine the association 
between OAC use and post-EVT reperfusion grade (eTICI) and func-
tional outcome (mRS) at 90 days, and binary logistic regression mod-
els for the associations with sICH, ischemic stroke progression, and 
90-day mortality. To estimate the association of OAC use with the 
NIHSS score 24 to 48 hours postintervention, we used linear regres-
sion models. Analyses were adjusted for important prognostic factors: 
age, baseline NIHSS score, prestroke mRS score, time from onset to 
start of EVT, intravenous thrombolysis, history of hypertension, dia-
betes mellitus, hypercholesterolemia, ischemic stroke, and prior use 
of antiplatelet agents. In the case of clinical outcomes (ie, NIHSS 
score, functional outcome, sICH, stroke progression, and mortality), 
we additionally adjusted for systolic blood pressure, baseline collat-
eral status, and ASPECT score. To compare functional outcome be-
tween patients with or without prior OAC use, we analyzed the shift 
on the mRS with ordinal logistic regression analysis.
Additionally, we performed subgroup analyses to evaluate the 
effect of the specific OAC types (ie, VKAs and DOACs) on the out-
comes. Besides, we compared outcomes in patients with prior VKA 
use according to INR subgroups (INR ≤1.7; 1.7–3.0; >3.0). Statistical 
analyses were performed with Stata/SE 14.1 (StataCorp, TX).
Results
Patient Characteristics
Between March 2014 and November 2017, 3637 patients 
were enrolled in MR CLEAN Registry. After exclusion of 
patients with age <18 (n=9), treatment in a non-MR CLEAN 
trial center (n=177), posterior circulation occlusion (n=172), 
onset to start of EVT >390 minutes (n=99), and missing in-
formation on OAC use (n=18), we included 3162 patients for 
the current study (Figure 1). Before EVT, OACs were used 
in 502 patients (16%), of whom 404 patients were on VKAs 
and 98 on DOACs. Median INR among VKA users was 1.8 
(interquartile range, 1.4–2.3).
Patients on OACs were older (median age 78 versus 71, 
P<0.01), had more severe neurological deficits at baseline 
(median NIHSS 17 versus 16, P<0.01), more comorbidities 
(ie, atrial fibrillation (78% versus 13%, P<0.01), diabetes 
mellitus (20% versus 15%, P=0.02), hypertension (64% 
versus 49%, P<0.01), hypercholesterolemia (34% versus 
29%, P<0.01)), and were less often treated with antiplate-
let agents before current stroke (11% versus 35%, P<0.01; 
Table 1). Patients on OACs more often had suffered from 
stroke in their medical history (28% versus 15%, P<0.01), 
and prestroke functional status was worse compared with 
patients not on OACs (pre-mRS 0 in 49% versus 70%, 
P<0.01). IVT were less frequently administered in patients 
on prior OACs (34% versus 84%; P<0.01). ASPECT score 
was slightly better in patients on OACs, with a score of 8 to 
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10 in 76% versus 72% in patients not on OACs (P=0.03). 
Occlusion locations and collateral scores were not statisti-
cally different between the groups.
Outcomes
The proportion of patients with successful reperfusion (eTICI 
2B or higher) was similar in both groups (61% for patients on 
OAC versus 64% in patients not on OAC; adjusted odds ratio, 
0.91 [95% CI, 0.70–1.18]), as well as the proportion of excel-
lent (eTICI 2C or higher) and complete (eTICI 3) reperfusion 
(Table 2). Intervention characteristics are shown in Table I in 
the Data Supplement.
NIHSS score at 24 to 48 hours postintervention was 
higher in patients on OAC compared with patients not on 
OAC (median 12 versus 10; β, 0.91 [95% CI, 0.02–1.80]). 
This difference was not statistically significant after adjust-
ment for prognostic factors (adjusted β, −0.46 [95% CI, 
−1.38 to 0.47]). The proportion of patients with improve-
ment of 4 or more points on the NIHSS was not different 
between groups (45% versus 49%; adjusted odds ratio, 1.01 
[95% CI, 0.78–1.31]).
There was no statistically significant difference in the 
occurrence of sICH between patients with and without prior 
OACs (5% versus 6%; adjusted odds ratio, 0.79 [95% CI, 
0.46–1.35]). Death within 90 days occurred more often in 
patients on OAC (38% versus 25%; OR, 1.82 [95% CI, 1.49–
2.23]) in the univariable analysis. However, after adjustment 
for prognostic factors, prior OAC use was not associated with 
an increased mortality at 90 days (adjusted odds ratio, 1.20 
[95% CI, 0.91–1.60; Table 2).
The mRS scores at 90 days were available in 2953/3162 
patients (93%). Functional independence (mRS score 0–2) 
was reached less often by patients using OAC (29% versus 
43%; OR, 0.54 [95% CI, 0.43–0.67]; Table 2). Use of OACs 
was associated with a shift towards worse outcomes on the 
mRS in the unadjusted analysis (cOR, 0.57 [95% CI, 0.47–
0.66]; mRS distribution is shown in Figure 2). However, there 
was no statistically significant difference after adjustment for 
baseline prognostic factors (acOR, 0.88 [95% CI, 0.71–1.10]; 
Table 2).
Subgroup and Sensitivity Analyses
The incidence of sICH was lower in patients on DOACs 
when compared with patients on VKAs (1/98, 1% versus 
23/404, 6%). However, functional outcome did not differ be-
tween patients on DOACs and VKAs (Table II in the Data 
Supplement). In patients with prior VKA use, complication 
risk and functional outcome was similar for INR subgroups 
≤1.7 and 1.7 to 3.0 (Table III in the Data Supplement). Only 8 
patients presented with a baseline INR >3.0, of whom one pa-
tient reached functional independence. Five of these 8 patients 
died within 90 days, of whom one from sICH.
Discussion
In this observational study representative of Dutch clinical 
practice, one out of 6 patients who underwent EVT for is-
chemic stroke was on prior OACs. Although the postpro-
cedural reperfusion status and risk of sICH were similar 
between patients on prior OAC use compared with patients 
without prior OAC use, outcomes were worse for OAC users 
with regard to neurological recovery and functional out-
come at follow-up. However, these observed differences 
disappeared after adjustments for imbalances in baseline 
Figure 1. Flowchart of patients included in the 
study. EVT indicates endovascular treatment; 
MR CLEAN, Multicenter Randomized Clinical 
Trial of Endovascular Treatment of Acute Is-
chemic Stroke in the Netherlands; and OAC, 
oral anticoagulant.
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prognostic factors. Therefore, EVT should not be withheld 
in prior OAC users.
Several observational studies reported on the prevalence 
of OAC use in patients eligible for mechanical thrombectomy, 
which ranged from 3% to 23%.14–24 The lowest prevalence was 
observed in studies which included patients from a very early 
period, from 1992 to 2002, respectively.15,17 Back then, EVT 
was new, which might have led to cautious attitude towards 
this treatment, resulting in exclusion of patients on OACs. 
Prevalence in our study was in the upper range, with 16% of 
Table 1. Baseline Characteristics of 3162 Patients Who Underwent EVT for Ischemic Stroke, Stratified for Prior OAC Use Versus No Prior OAC Use
OAC n=502 Non-OAC n=2660 P Value Missing, n (%)
Age, median (IQR) 78 (69–84) 71 (60–80) <0.01 0 (0)
Male sex, n (%) 262 (52) 1384 (52) 0.95 0 (0)
NIHSS, median (IQR) 17 (12–20) 16 (11–19) <0.01 49 (2)
Clinical localization: left hemisphere, n (%) 285 (57) 1389 (52) 0.12 2 (0)
Systolic blood pressure, mean mm Hg (SD) 148 (26) 150 (25) 0.12 85 (3)
Intravenous alteplase treatment, n (%) 173 (34) 2239 (84) <0.01 10 (0)
Medical history
Atrial fibrillation, n (%) 394 (78) 359 (13) <0.01 36 (1)
Hypertension, n (%) 322 (64) 1300 (49) <0.01 60 (2)
Diabetes mellitus, n (%) 98 (20) 407 (15) 0.02 18 (1)
Hypercholesterolemia, n (%) 173 (34) 764 (29) <0.01 131 (4)
Ischemic stroke, n (%) 143 (28) 387 (15) <0.01 22 (1)
Prior antiplatelet use, n (%) 54 (11) 926 (35) <0.01 27 (1)
Prestroke mRS score, n (%)   <0.01 71 (2)
  0 248 (49) 1850 (70)   
  1 96 (19) 309 (12)   
  2 50 (10) 176 (7)   
  >2 98 (20) 264 (10)   
Imaging
Level of occlusion on noninvasive vessel imaging 
(CTA), n (%)
  0.07 155 (5)
ICA (intracranial) 12 (2) 143 (5)   
ICA-T 109 (22) 525 (20)   
M1 280 (56) 1476 (55)   
M2 72 (14) 366 (14)   
Other: M3 and ACA 3 (1) 21 (1)   
ASPECTS subgroups   0.03 105 (3)
0–4, n (%) 14 (3) 129 (5)   
5–7, n (%) 87 (17) 540 (20)   
8–10, n (%) 381 (76) 1906 (72)   
Collaterals   0.31 202 (6)
Grade 0, n (%) 37 (7) 147 (6)   
Grade 1, n (%) 167 (33) 899 (34)   
Grade 2, n (%) 186 (37) 960 (36)   
Grade 3, n (%) 81 (16) 483 (18)   
Transfer from primary stroke center, n (%) 269 (54) 1467 (55) 0.51 1 (0)
Onset to arterial puncture (minutes), median (IQR) 190 (148–250) 195 (150–250) 0.56 14 (0)
ACA indicates anterior cerebral artery; ASPECTS, Alberta Stroke Program Early CT Score; CTA, computed tomography angiography; EVT, endovascular 
treatment; ICA, internal carotid artery; ICA-T, internal carotid artery terminus; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, National 
Institutes of Health Stroke Scale; and OAC, oral anticoagulant.
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EVT eligible patients on OACs, and consistent with current 
practice described in most recently reported studies.21,23
In theory, prior OAC use may facilitate successful reper-
fusion, as the pharmacological mechanism is to reduce fibrin 
formation and, therefore, might reduce thrombus formation. 
On the contrary, achievement of successful reperfusion might 
be impaired by composition of the thrombus in cardio-embolic 
stroke (more prevalent in patients on OAC), which may be 
more difficult to retrieve.25 Nevertheless, successful reperfu-
sion was not significantly different between the groups in our 
study, consistent with previous studies.15,16,19–22,25
As in the majority of previous studies evaluating prior OAC 
use in EVT treated patients, risk of sICH was not increased, 
and even lower for patients on OACs in our study.14–17,19–22 This 
finding could partly be due to the fact that IVT was withheld 
more often in patients who were on prior OACs (34% versus 
Table 2. Outcomes of 3162 Patients Who Underwent EVT for Ischemic Stroke, Stratified for Prior OAC Use Versus No Prior OAC Use
OAC Use Non-OAC Use Effect Estimates (95% CI)*
(n=502) (n=2660) Unadjusted Adjusted
sICH, n (%) 24 (5) 162 (6) 0.77 (0.50 to 1.20) 0.79 (0.46 to 1.35)
Hemorrhage type, n (%)
  PH2 5 (21) 94 (58)   
  PH1 10 (42) 33 (20)   
  rPH 1 (4) 22 (14)   
  SAH 17 (71) 80 (49)   
  IVH 5 (21) 74 (46)   
Ischemic stroke progression, n (%) 37 (7) 244 (9) 0.79 (0.55 to 1.13) 0.74 (0.48 to 1.15)
Mortality at 90 d, n (%) 190 (38) 662 (25) 1.82 (1.49 to 2.23) 1.20 (0.91 to 1.60)
mRS at 90 d, median (IQR)† 4 (2-6) 3 (2-6) 0.57 (0.47 to 0.66) 0.88 (0.71 to 1.10)
mRS 0–1 at 90 d, n (%)† 73 (15) 589 (24) 0.56 (0.43 to 0.73) 0.85 (0.60 to 1.19)
mRS 0–2 at 90 d, n (%)† 140 (29) 1058 (43) 0.54 (0.43 to 0.67) 0.86 (0.63 to 1.17)
mRS 0–3 at 90 d, n (%)† 206 (43) 1386 (56) 0.58 (0.47 to 0.70) 0.93 (0.70 to 1.23)
NIHSS postintervention (24 h), median (IQR)‡ 12 (5 to 18) 10 (4 to 17) β 0.91 (0.02 to 1.80) β −0.46 (−1.38 to 0.47)
Improvement on the NIHSS of ≥4 points, n (%) 224 (45) 1297 (49) 0.85 (0.69 to 1.04) 1.01 (0.78 to 1.31)
Successful reperfusion (eTICI 2B or higher)§, n (%) 263 (61) 1440 (64) 0.86 (0.70 to 1.07) 0.91 (0.70 to 1.18)
Excellent reperfusion (eTICI 2C or higher)§, n (%) 187 (43) 979 (43) 0.99 (0.80 to 1.21) 1.07 (0.84 to 1.36)
Complete reperfusion (eTICI 3)§, n (%) 134 (31) 709 (31) 0.97 (0.78 to 1.22) 1.08 (0.83 to 1.40)
ASPECTS indicates Alberta Stroke Program Early CT Score; EVT, endovascular treatment; eTICI, extended Thrombolysis in Cerebral Ischemia; IQR, interquartile range; 
mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OAC, oral anticoagulant; and sICH, symptomatic intracranial hemorrhage.
*(Common) odds ratios, unless otherwise indicated. Analyses were adjusted for age, baseline NIHSS score, prestroke mRS score, time from onset to start of EVT, 
intravenous thrombolysis, history of hypertension, diabetes mellitus, hypercholesterolemia, ischemic stroke, and prior antiplatelet use. In the case of clinical outcomes, 
we additionally adjusted for systolic blood pressure, baseline collateral status and ASPECTS.
†n=2953 (mRS score at 90 d was missing for 209 patients).
‡n=2841 (postintervention NIHSS score was missing for 321 patients).
§n=2685 (patients who underwent an attempt for thrombectomy).
Figure 2. Functional outcome on the modified Rankin Scale (mRS); n=2953 (mRS score at 90 d was missing for 209 patients). OAC indicates oral 
anticoagulant.
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84% in no OAC users), which may have resulted in a lower 
bleeding risk in this group. Nevertheless, after adjustment for 
IVT in regression analyses, the association with lower risk of 
sICH for patients on OAC persisted.
A previous meta-analysis showed that patients on OACs 
reached functional independence less often compared with 
nonusers.26 In line with our study, this difference could not 
be explained by differences in recanalization or occurrence of 
sICH, but by older age and more cardiac co-morbidity. Three 
observational studies, thereafter, reported similar findings to 
our study with respect to functional outcome.6,22–24 One mul-
ticenter study from the Madrid Stroke Network, however, re-
ported similar functional outcome.21 In this study, DOAC use 
was suggested to have a positive influence compared with the 
most frequently reported use of VKAs. However, only 8% of 
OAC users were on DOACs, compared with 20% in our study. 
Other explanations could have been baseline imbalances con-
cerning right hemispheric and vertebrobasilar stroke, and 
lower NIHSS score in patients on OACs in that study.
Only few small observational studies investigated the re-
lation between INR and risk of sICH after EVT. Increasing 
INR did not result in higher risk of ICH according to a small 
observational study.20 Three small observational studies in-
cluded 18, 21, and 10 patients who underwent EVT with INR 
>1.7.17,27,28 In these studies, the risk of sICH or poor functional 
outcome were not increased for patients with INR >1.7. Only 
in one other small 2-center study with 21 patients, occurrence 
of sICH was increased (18% versus 7%) in patients with INR 
>1.7, but the difference was not significant. In our study, we 
found similar sICH rate and functional outcome compared 
with patients on VKAs with INR ≤1.7. Of note, only 8 patients 
with INR >3 were included in the study. Even though 5 of 
these patients died, only one died from sICH, which suggests 
hemorrhagic diathesis was not the primary cause of death. 
Nevertheless, strong conclusions about the safety of EVT in 
patients with INR >3 should not be drawn from this small 
sample size.
This study has some limitations. First, we reported ob-
servational, nonrandomized data. This might have resulted in 
confounding by indication, because patients on OACs were 
mainly patients with risk of cardio-embolic stroke and had 
cardiac co-morbidity with potential influence on outcomes. 
We adjusted for these prognostic factors in the regression 
analyses. However, this confounding may not be eliminated 
completely. Second, we were unable to report the time elapsed 
between administration of OACs and puncture for EVT. This 
may have had influence on hemorrhagic diathesis during and 
after the interventional procedure. Third, patients who were 
excluded from receiving EVT because of OAC use were not 
registered. However, we expect this number to be limited be-
cause in Dutch practice the standard is to treat patients with 
thrombectomy regardless of OAC use and an INR up to 3, or 
in some centers without INR limit.
Conclusions
Prior OAC use is not associated with an increased risk of 
sICH or worse functional outcome in patients treated with 
EVT for acute ischemic stroke compared with no prior OAC 
use. Therefore, prior OAC use should not be a contra-indi-
cation for EVT.
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